Arcbest Corp (ARCB)
$28.03 0.05 (0.18%)
16:00 EDT ARCB Stock Quote Delayed 30 Minutes
Previous Close $28.03
Market Cap 718.73M
PE Ratio 9.63
Volume (Avg. Vol.) 182,900
Day's Range 27.62 - 28.14
52-Week Range 13.54 - 32.46
Dividend & Yield 0.32 (1.14%)
ARCB Stock Predictions, Articles, and Arcbest Corp News
- From InvestorPlace
- From the Web
These stocks to buy are all undervalued in today's market. Here's what investors need to know about each of these stocks' growth prospects.
Broker advice is highly sought after by investors as they strive to design a winning portfolio of stocks, irrespective of market conditions. Compare Brokers....
In value investing, investors pick stocks that are cheap but fundamentally sound. So, the chance of outperformance is high when the market moves higher. Compare....
A number of Wall Street strategists remained bullish about the outlook for American equities given the expectations of double-digit earnings growth, accelerated....
As yields rise, investors may find dividend growing stocks and ETFs as safer bets. Compare Brokers...
Did Changing Sentiment Drive Taro Pharmaceutical Industries’ (NYSE:TARO) Share Price Down A Worrying 54%?
From Simply Wall St
While not a mind-blowing move, it is good to see that the Taro Pharmaceutical Industries Ltd. (NYSE:TARO) share price has gained 10% in the last three months. But over the<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-taro/taro-pharmaceutical-industries/news/did-changing-sentiment-drive-taro-pharmaceutical-industries-nysetaro-share-price-down-a-worrying-54/">Read More...</a></div>
Here’s What Analysts Are Forecasting For Taro Pharmaceutical Industries Ltd. (NYSE:TARO) After Its Full-Year Results
From Simply Wall St
It’s been a good week for Taro Pharmaceutical Industries Ltd. (NYSE:TARO) shareholders, because the company has just released its latest full-year results, and the shares gained 7.0% to US$70.05. Taro<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-taro/taro-pharmaceutical-industries/news/heres-what-analysts-are-forecasting-for-taro-pharmaceutical-industries-ltd-nysetaro-after-its-full-year-results/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader